ArticleHaematologica2021
MK2 is a therapeutic target for high-risk multiple myeloma.
Chunyan Gu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
10 papers cite it
this papercites it
ArticleHaematologica2021
Chunyan Gu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.